Bullish
Johnson & Johnson's ICOTYDE® shows sustained efficacy in plaque psoriasis treatment.
Johnson & Johnson announced positive two-year data from the Phase 3 ICONIC-TOTAL study, demonstrating that ICOTYDE® (icotrokinra) effectively treats difficult-to-manage plaque psoriasis. The study revealed that nearly 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved complete skin clearance at Week 112. These results affirm ICOTYDE®'s potential as a first-line systemic therapy for plaque psoriasis. ([jnj.com](https://www.jnj.com/media-center/press-releases?utm_source=openai))
Key points
- ICOTYDE® demonstrates high efficacy in treating difficult-to-manage plaque psoriasis.
- No significant market-moving news reported in the last 24 hours.
Sources
AI-generated from public news sources. Not financial advice.
